Vaccitech has warned of the risk of blood clots when presenting an IPO
Vaccitech, the owner of the technology behind the AstraZeneca vaccine, has warned that concerns about the rare side effect of blood clotting could lead to royalty and the popularity of its pipeline products.
The Oxford University spinout was released on Friday initial public offering at least $ 100 million on Nasdaq, the UK and several EU countries by the end of the week recommended against vaccinating younger people.
The presentation revealed how much should be received from vaccine sales. If AstraZeneca starts selling for profit after the pandemic and under contract it could be in July 2021. Oxford will give him about a quarter of the rights he received from the vaccine Vaccitech, approximately 1.4% of total net sales.
The company received a single payment of $ 2.5 million last year when it transferred the technology behind the Oxford / AstraZeneca vaccine.
Vaccitech is developing vaccines against other infectious diseases, including the virus behind shingles and Mersen, another coronavirus, as well as using the same vector technology to treat cancer and chronic hepatitis.
The pandemic has helped the company prove its operation to millions of people when many biotechnologies go public with little or no clinical research data. The rapid development and manufacture of the AstraZeneca vaccine has helped demonstrate that Vaccitech’s technology can be scaled quickly.
But while the Oxford / AstraZeneca vaccine, known as AZD1222, has been shown to be safe and effective, recent concerns about very rare side effects now carry the perception weight of the shot.
“It cannot be assured that the vaccine is not associated with an increased risk of thromboembolic events,” the company wrote in the archive.
Vaccitech also warns that research showing the AstraZeneca vaccine may not be as effective as it could affect sales against the first identified variant in South Africa.
Latest coronavirus news
Follow the FT’s live coverage and analysis of the global pandemic and the rapidly developing economic crisis here.
“Any combination of AZD1222 with adverse events or perceptions of that association or a more effective finding against certain variants of AZD1222 Covid-19 may reduce AZD1222’s sales and therefore payments we may receive for net sales. Vaccine, and otherwise in the development of our product candidates and it can affect our ability to market, ”he said.
Vaccitech’s decision to list New York is a disappointment for the UK as it hopes to attract more investment in the life sciences. The UK Treasury has a stake in the company, according to people close to the situation.
The largest investor is Oxford Sciences Innovation, a start-up venture capital firm focused on marketing university intellectual property, with a 29 per cent stake before the offer. Major shareholders include Prudential insurer, which has a 13 percent stake, and Google Ventures-affiliated organizations, which own 6 percent.